ArticleMolecular genetics and genomics : MGG2026
Expression, prognostic value and function of LMBR1L in gastric cancer.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastric cancer remains a leading cause of cancer-related death worldwide, and effective prognostic biomarkers are urgently needed to guide clinical management. This study aimed to investigate the role of LMBR1L in gastric cancer. The expression of LMBR1L protein was detected by immunohistochemistry, Western blot and other methods. An LMBR1L knockdown HGC-27 cell line was constructed, and a xenograft experiment in nude mice was conducted to verify its effect on tumor growth in vivo. In addition, a nomogram model was constructed based on the expression level of LMBR1L and other clinical indicators to evaluate its predictive value for postoperative survival of gastric cancer patients. LMBR1L was highly expressed in gastric cancer. Patients with high expression of LMBR1L had lower postoperative overall survival (OS) and disease-free survival (DFS) rates than those with low expression. LASSO regression and Cox multivariate analysis showed that the expression level of LMBR1L was an independent risk factor for the prognosis of gastric cancer patients. The nomogram model constructed based on LMBR1L and other clinical indicators had a good predictive value for postoperative survival of gastric cancer patients, with areas under the ROC curve (AUC)of 0.642, 0.691 and 0.690 for 1-, 3- and 5-year survival rates, respectively. The xenograft experiment in nude mice indicated that knockdown of LMBR1L could significantly inhibit the development of gastric cancer in vivo. LMBR1L is highly expressed in gastric cancer and is closely related to poor prognosis of patients. Its regulatory effects on the biological behavior of gastric cancer in vitro and in vivo further confirm its important value as a prognostic biomarker and potential therapeutic target for gastric cancer, providing new insights into the molecular mechanisms of gastric cancer progression.
Indexed as
Identifiers
42371227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.